{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009175","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.894541+00:00","generated_at":"2026-06-17T21:12:08.198108+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assembly Bio prioritizes ABI-4334, pauses ABI-H3733 on chronic toxicology finding; Q4 2022 net loss $93.1M","bullets":["Phase 1a for ABI-4334 complete for single-dose and 100mg multiple-dose; half-life supports once-daily dosing; 200mg data expected April.","Phase 1b for ABI-H3733: all 7 HBeAg-negative patients achieved HBV DNA below LLOQ by day 21; chronic toxicology in one species halted program.","Net loss $93.1M ($1.92/share) for FY2022 vs $129.9M ($3.00/share) in 2021; cash $91.6M as of Dec 31, 2022, funding into mid-2024.","Second development candidate nomination expected in 2023; IND/CTA for herpesvirus candidate ABI-5366 planned for first half 2024.","CEO Jason Okazaki appointed as previously reported; no new leadership change in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009175","json":"https://secwatch.observer/filing/0000950170-23-009175.json","markdown":"https://secwatch.observer/filing/0000950170-23-009175.md","text":"https://secwatch.observer/filing/0000950170-23-009175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023009175/0000950170-23-009175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023009175/asmb-20230322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:12:08.198108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d22d95a6a4696697d4612ea280fb712e333d35f7","claim":"ASSEMBLY BIOSCIENCES, INC. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 22, 2023, Assembly Biosciences, Inc. (the \"Company\") issued a press release (the \"Press Release\") announcing its financial results for the quarter and year ended December 31, 2022 and recent corporate highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023009175/0000950170-23-009175-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}